

PERSONALIZED CARE for von Willebrand Disease IN THE REAL WORLD

One size *doesn't* fit all

Tuesday, June 27, 2023 | 13:15-14:30 ET

Join our expert panel of speakers who will discuss the burden of von Willebrand disease (VWD), and explore the importance and benefits of personalized therapy, as demonstrated by patient case studies

This symposium will be chaired by **Paula James**, who will review the burden of disease for individuals with VWD, and the benefits and barriers to prophylaxis. **Robert F Sidonio Jr** will then discuss the value of pharmacokinetic tailored dosing to personalize care for individuals with VWD. Next, **Sophie Susen**, **Miguel Escobar**, and **Michelle Lavin** will each present a patient's case, spotlighting different types of bleeds, including joint bleeding, gastrointestinal bleeding associated with angiodysplasia, and heavy menstrual bleeding.

Time (ET)	Title	Faculty
13:15-13:17	Welcome and introduction	Paula James
13:17-13:30	Burden of disease for individuals with von Willebrand disease and the benefits and barriers to prophylaxis	Paula James
13:30-13:40	Personalized care for individuals with von Willebrand disease: The value of pharmacokinetic-tailored dosing	Robert F Sidonio Jr
13:40-13:50	Patient with frequent joint bleeds	Sophie Susen
13:50-14:00	Patient with gastrointestinal bleeding and angiodysplasia	Miguel Escobar
14:00-14:10	Patient with heavy menstrual bleeding	Michelle Lavin
14:10-14:30	Panel discussion and Q&A	All



Paula James (Chair)
Queen's University,
Ontario, Canada



Robert F Sidonio Jr
Emory University,
Atlanta, GA, USA



Sophie Susen
University of Lille,
Lille, France



Miguel Escobar
University of Texas,
Houston, TX, USA



Michelle Lavin
Royal College of
Surgeons in Ireland,
Dublin, Ireland



This Isth-authorized symposium is initiated, organized, and funded by Takeda, and intended only for healthcare professionals registered for the Isth Congress 2023. Please be advised that this is a non-CME event and that Takeda products will be discussed. Products and/or indicated uses discussed may not have received marketing authorization for sale in Canada. For products that have received marketing authorization in Canada, always refer to the current Canadian Product Monograph for prescribing information. Copyright 2023. Takeda Pharmaceutical Company Limited. All rights reserved. Takeda and the Takeda logo are registered trademarks of Takeda Pharmaceutical Company Limited. VV-MEDMAT-80656 04/2023

